Healthcare provider profile · identity verified

Manuel Sanchez Tu, MD

Family Practice · BAKERSFIELD, CA · NPI 1104387406

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	502	229
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	282	73
Lisinopril	Lisinopril	271	126
Losartan Potassium	Losartan Potassium	234	110
Amlodipine Besylate	Amlodipine Besylate	209	97
Albuterol Sulfate Hfa	Albuterol Sulfate	163	87
Levothyroxine Sodium	Levothyroxine Sodium	162	70
Gabapentin	Gabapentin	149	55
Pantoprazole Sodium	Pantoprazole Sodium	148	67
Alendronate Sodium	Alendronate Sodium	143	53
Rosuvastatin Calcium	Rosuvastatin Calcium	141	69
Metformin Hcl	Metformin Hcl	120	47
Tamsulosin Hcl	Tamsulosin Hcl	116	59
Glipizide	Glipizide	111	54
Omeprazole	Omeprazole	111	48
Tramadol Hcl	Tramadol Hcl	105	32
Metformin Hcl Er	Metformin Hcl	100	51
Ozempic	Semaglutide	95	24
Meloxicam	Meloxicam	88	39
Potassium Chloride	Potassium Chloride	85	42
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	84	35
Simvastatin	Simvastatin	71	33
Atenolol	Atenolol	70	32
Metoprolol Tartrate	Metoprolol Tartrate	70	29
Allopurinol	Allopurinol	65	23
Furosemide	Furosemide	63	30
Arexvy	Rsvpref3 Antigen/As01e/Pf	58	58
Hydrochlorothiazide	Hydrochlorothiazide	58	28
Trazodone Hcl	Trazodone Hcl	58	31
Mirtazapine	Mirtazapine	55	24
Pradaxa	Dabigatran Etexilate Mesylate	54	23
Amoxicillin	Amoxicillin	53	50
Hydralazine Hcl	Hydralazine Hcl	50	16
Metoprolol Succinate	Metoprolol Succinate	47	22
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	44	42
Clopidogrel	Clopidogrel Bisulfate	43	22
Triamcinolone Acetonide	Triamcinolone Acetonide	42	28
Jardiance	Empagliflozin	41	13
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	41	17
Famotidine	Famotidine	40	22
Buspirone Hcl	Buspirone Hcl	37	14
Humulin N Kwikpen	Insulin Nph Human Isophane	37	16
Terazosin Hcl	Terazosin Hcl	37	15
Humulin N	Insulin Nph Human Isophane	36	17
Lactulose	Lactulose	36	17
Morphine Sulfate Er	Morphine Sulfate	34	suppressed
Finasteride	Finasteride	33	14
Prednisone	Prednisone	33	24
Sumatriptan Succinate	Sumatriptan Succinate	33	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	33	16
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Ondansetron Odt	Ondansetron	31	15
Carvedilol	Carvedilol	30	13
Ibuprofen	Ibuprofen	29	19
Topiramate	Topiramate	28	suppressed
Baclofen	Baclofen	26	suppressed
Clonazepam	Clonazepam	25	suppressed
Spiriva Respimat	Tiotropium Bromide	25	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	24	11
Nitroglycerin	Nitroglycerin	24	suppressed
Alvesco	Ciclesonide	23	13
Acyclovir	Acyclovir	22	11
Ezetimibe	Ezetimibe	22	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	22	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	21	19
Pioglitazone Hcl	Pioglitazone Hcl	21	suppressed
Sertraline Hcl	Sertraline Hcl	21	13
Lorazepam	Lorazepam	20	14
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	20	17
Testosterone	Testosterone	20	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	18	18
Colchicine	Colchicine	18	suppressed
Eliquis	Apixaban	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Alprazolam	Alprazolam	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	17
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Montelukast Sodium	Montelukast Sodium	16	suppressed
Nystatin	Nystatin	16	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	16	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	15	suppressed
Clobetasol Propionate	Clobetasol Propionate	15	11
Clonidine Hcl	Clonidine Hcl	15	suppressed
Mupirocin	Mupirocin	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Humulin R	Insulin Regular, Human	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Lidocaine Hcl Viscous	Lidocaine Hcl	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Clozapine	Clozapine	13	suppressed
Naproxen	Naproxen	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Ramelteon	Ramelteon	13	suppressed
Risedronate Sodium	Risedronate Sodium	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Temazepam	Temazepam	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Ciclopirox	Ciclopirox	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error